News
Displaying 321–330 of 508
-
FDA Wins Case against Stem-Cell Clinic that Blinded Patients with Bogus Treatment
Research NewsA federal court ruled that the FDA has regulatory authority over these stem-cell procedures and the power to halt them.
-
Tackling the Next Gene Therapy Challenge: Autosomal Dominant Diseases
Foundation NewsA discussion of strategies concerning the development of autosomal dominant disease therapies at the Translational Research Acceleration Program (TRAP) in November 2013.
-
Dr. Don Zack Honored for Research Contributions by ARVO and the Foundation Fighting Blindness
Research NewsDr. Zack is a member of the Foundation’s Scientific Advisory Board and chairs its Cellular Molecular Mechanisms of Disease study section.
-
Research News
Eye Bonds provide the opportunity to advance, and accelerate development for, more promising treatments into and through clinical trials and out to the people who need them.
-
Foundation Fighting Blindness Endorses 'Eye Bonds' Legislation
Foundation NewsBipartisan Bill Will Stimulate Up to $1 Billion in New Funding for Blindness Research
-
ARVO 2019: Gene Therapy Clinical Trial for RP Caused by RLBP1 Mutations Ongoing in Sweden
Research NewsIn a Novartis lab study, mice with RLBP1 mutations had improved dark adaptation after receiving the gene therapy. The treatment remained effective after one year.
-
ARVO 2019: Robot-Assisted Surgery in Clinical Trial for Retinal Disease
Research NewsA video from a clinical trial of robot-assisted surgery demonstrates the potential benefits of robot-assisted subretinal injections.
-
ARVO 2019: Emerging Eloxx Molecules Show Promising Results in Usher Models
Research NewsEloxx Pharmaceuticals is developing small molecules that permit read-through of point mutations that cause Usher syndrome 1F and 2A.
-
ARVO 2019: Emerging Drug for RP Evaluated in Safety & Tolerability Study
Research NewsFrancois Paquet-Durand, PhD, chief scientific officer at the company Mireca, discusses an emerging drug for retinitis pigmentosa, and other inherited retinal diseases.
-
REGENXBIO’s Gene Therapy for Wet AMD Performing Encouragingly in Human Study
Research NewsUnlike current treatments requiring multiple injections, REGENXBIO’s gene therapy is administered as a one-time subretinal injection to the affected eye.
